Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on the market in the coming years with the remarkable progress of an extensive pipeline, that premier late-stage pipeline is highlighted by its industry-leading neurological and cardiometabolic franchises. In late 2021, the company entered into a joint development and commercialization agreement to develop and commercialize eplonterson. Phase III studies are in the final stages and preparations are being made for commercialization. The critical hire of the Amyloidosis Medical Director was essential to Shay Bujanover’s Medical Affairs team, and The Chase Group is pleased to announce the placement of Veena Narayan, PhD, into the role. Dr. Narayan brings a depth of neuroscience education and experience to the team, including industry medical affairs strategy, launch, and co-commercialization expertise. If you seek a strong partnership with your executive search firm, we welcome the opportunity to work with you. Let us help you build your leadership team and experience the impact The Chase Group can have on your company’s success/growth. To learn more, email karen@chasegroup.com.
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on the market in the coming years with the remarkable progress of an extensive pipeline, that premier late-stage pipeline is highlighted by its industry-leading neurological and cardiometabolic franchises. In late 2021, the company entered into a joint development and commercialization agreement to develop and commercialize eplonterson. Phase III studies are in the final stages and preparations are being made for commercialization. The critical hire of the Amyloidosis Medical Director was essential to Shay Bujanover’s Medical Affairs team, and The Chase Group is pleased to announce the placement of Veena Narayan, PhD, into the role. Dr. Narayan brings a depth of neuroscience education and experience to the team, including industry medical affairs strategy, launch, and co-commercialization expertise. If you seek a strong partnership with your executive search firm, we welcome the opportunity to work with you. Let us help you build your leadership team and experience the impact The Chase Group can have on your company’s success/growth. To learn more, email karen@chasegroup.com.- Categories: Biotechnology, Life Sciences, Pharmaceutical
Ionis Director, Global HEOR, Rare Disease Immunology, Successfully Placed by The Chase Group
Ami Claxton, MS, PhD has joined Ionis Pharmaceuticals, Inc. as Director, Global HEOR Rare Disease Immunology. She will play a critical and significant role as…
Successful Placement at Avidity
The Chase Group is pleased to announce the successful completion of the Vice President, Medical Affairs search for Avidity Biosciences. Nathan Weedin brings 15+ years…
The Chase Group Successfully Completes Search for Amyloidosis Medical Affairs Leader
Ionis Pharmaceuticals has a 35-year track record of perfecting and advancing RNA-targeted drug discovery and development. Projecting a vast number of new transformational products on…
The Chase Group Identifies Chief Medical Officer for Arcturus Therapeutics
In late 2022, Arcturus Therapeutics retained The Chase Group to build out additions to the leadership team. Tasked with identifying the new Chief Medical Officer,…
The Chase Group Secures VP, Head of Regulatory Affairs, for Checkmate Pharmaceuticals
The Chase Group is pleased to announce the successful recruitment of Elvis Osei Tutu, PharmD, as the Vice President, Head of Regulatory Affairs at Checkmate…
The Chase Group Secures Clinical Operations Leadership for Alexza Pharmaceuticals
The Chase Group, committed to executive recruitment in life sciences, is pleased to announce the completion of another search for Alexza Pharmaceuticals, successfully securing Mike…